Mersana Therapeutics, Inc. (MRSN) closed the last trading session at $8.11, gaining 0.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $28.29 indicates a 248.8% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $16.09. While the lowest estimate of $8.00 indicates a 1.4% decline from the current price level, the most optimisti ...

Group 1 - Aris Mining Corporation (ARMN) closed at $7.19, with a 5.7% gain over the past four weeks, and has a mean price target of $9.36, indicating a 30.2% upside potential [1] - The average price targets range from a low of $8.72 to a high of $10.08, with a standard deviation of $0.58, suggesting a 21.3% increase at the lowest estimate and a 40.2% increase at the highest [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 11.8% over the past month [11][12] Group 2 - ARMN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - The consensus price target, while not entirely reliable, indicates a positive direction for ARMN's stock price movement [14] - Analysts' optimistic outlook on ARMN's earnings prospects correlates with potential near-term stock price movements [11]

Group 1 - Carter Bankshares, Inc. (CARE) shares have increased by 3.4% over the past four weeks, closing at $17.93, with a mean price target of $22.67 indicating a potential upside of 26.4% [1] - The mean estimate includes three short-term price targets with a standard deviation of $1.53, where the lowest estimate of $21.00 suggests a 17.1% increase, and the highest estimate of $24.00 indicates a 33.9% increase [2] - Analysts show a strong consensus that CARE will report better earnings than previously estimated, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for CARE has increased by 10.4% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - CARE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Exact Sciences (EXAS) shows potential for significant upside, with a mean price target of $68.55 indicating a 26.2% increase from the current price of $54.3 [1] Price Targets and Analyst Consensus - The average price target consists of 22 estimates ranging from $54.00 to $90.00, with a standard deviation of $7.85, indicating variability in analyst predictions [2] - The lowest estimate suggests a minor decline of 0.6%, while the highest indicates a potential upside of 65.8% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about EXAS's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the past 30 days, one estimate has increased, leading to a Zacks Consensus Estimate rise of 255.6% [12] - EXAS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][7] - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [10]

Core Viewpoint - LendingClub (LC) shares have increased by 14.5% in the past four weeks, closing at $12.25, with a mean price target of $15.35 indicating a potential upside of 25.3% [1] Price Targets and Analyst Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $2.75, where the lowest estimate is $12.00 (indicating a 2% decline) and the highest is $19.50 (indicating a 59.2% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about LC's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] - The Zacks Consensus Estimate for the current year has risen by 2.8% over the past month, with no negative revisions [12] - LC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not be reliable for predicting exact stock gains, they can provide a directional guide for potential price movements [14]

Group 1 - Euroseas Ltd. (ESEA) shares have increased by 18.4% over the past four weeks, closing at $44.78, with a mean price target of $56 indicating a potential upside of 25.1% [1] - The average price targets range from a low of $51.00 to a high of $60.00, with a standard deviation of $4.58, suggesting a relatively high agreement among analysts [2] - Analysts show strong agreement on ESEA's ability to report better earnings than previously predicted, which supports the expectation of an upside [4][11] Group 2 - The Zacks Consensus Estimate for ESEA's current year earnings has increased by 4.4% over the last 30 days, with no negative revisions [12] - ESEA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement, which is a useful guide [14]

West Pharmaceutical Services (WST) closed the last trading session at $223.77, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $284 indicates a 26.9% upside potential.The average comprises 10 short-term price targets ranging from a low of $245 to a high of $355, with a standard deviation of $34.94. While the lowest estimate indicates an increase of 9.5% from the current ...

Group 1 - BILL Holdings (BILL) shares have increased by 2% over the past four weeks, closing at $45.62, with a mean price target of $66.75 indicating a potential upside of 46.3% [1] - The average of 24 short-term price targets ranges from a low of $40 to a high of $120, with a standard deviation of $20.19, suggesting variability in analyst estimates [2] - Analysts show a consensus that BILL will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for BILL's current year earnings has increased by 103.8% over the last 30 days, with seven estimates moving higher and no negative revisions [12] - BILL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While price targets may not be reliable indicators of stock gains, the direction implied by these targets appears to be a good guide for potential price movement [13]

Catalyst Pharmaceutical (CPRX) closed the last trading session at $24.96, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34 indicates a 36.2% upside potential.The average comprises eight short-term price targets ranging from a low of $31 to a high of $40, with a standard deviation of $2.98. While the lowest estimate indicates an increase of 24.2% from the current pri ...

Core Viewpoint - Provident Financial (PFS) shows potential for significant upside, with a mean price target of $21.50 indicating a 28.1% increase from the current price of $16.78 [1] Price Targets and Analyst Consensus - The average price targets from analysts range from a low of $18 to a high of $24, with a standard deviation of $2.17, suggesting a moderate agreement among analysts [2] - The lowest estimate indicates a 7.3% increase, while the highest suggests a 43% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about PFS's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.3%, with two estimates moving higher and no negative revisions [12] - PFS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]